ClinicalTrials.gg
Not yet recruitingNCT06947226Updated Apr 27, 2025

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

A Phase 1/2 interventional study of 9MW2821 and Other anti-cancer therapy in Solid Tumors, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
188
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved form.
  2. Male or female subjects aged 18 to 75 years (including 18 and 75 years).
  3. (ECOG) performance status of 0 or 1.
  4. Histopathological diagnosed of recurrent or locally advanced or solid tumors.
  5. Adequate tumor tissues submitted for test.
  6. of ≥ 12 weeks.
  7. Subjects must have according to (version 1.1).
  8. Adequate organ functions.
  9. Sexually active fertile subjects, and their partners, must agree to use during the study and at least 6 months after termination of study therapy.
  10. Subjects are willing to follow study procedures.

Exclusion criteria

Exclusion Criteria:

  1. History of another within 3 years before the first dose of study drug.
  2. Ongoing toxicities related to prior treatment.
  3. Grade ≥ 2 peripheral neuropathy.
  4. Severe or uncontrolled gastrointestinal diseases.
  5. Other severe or uncontrolled diseases, including severe respiratory diseases, cardiovascular and cerebrovascular diseases of clinical significance.
  6. Experienced clinically significant bleeding or had a clear bleeding tendency.
  7. Central nervous system (CNS) and/or malignant meningitis.
  8. Clinically significant pleural, abdominal, or pericardial effusion.
  9. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug;
  10. Known sensitivity to any of the ingredients of the product; History of drug abuse or mental illness.
  11. Pregnant and lactating women.
  12. Other conditions that, in the Investigator's opinion, may not be suitable for the subject to be enrolled.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    Combination Cohort

    Subjects will receive intravenous (IV) infusion of 9MW2821 + other anticancer therapy as per protocol

    Drug: 9MW2821 · Drug: Other anti-cancer therapy

  • Experimental
    Single agent Cohort

    Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

    Drug: 9MW2821

Interventions

  • Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

  • DrugOther anti-cancer therapy

    Subjects will receive other anticancer therapy as per protocol

06

What researchers measure

Primary outcomes

  1. Incidence of AE/SAE (phase Ib)

    Adverse event (AE), serious adverse event (SAE)

    Time frame: Up to approximately 24 months

  2. Objective Response Rate, ORR (phase II)

    The proportion of participants with complete response (CR) or partial response (PR)

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Duration of Response, DOR

    Time from the date of the first CR or PR to the earliest date of disease progression or death

    Time frame: Up to approximately 24 months

  2. Time To Response, TTR

    Time from the date of first infusion to the date of CR or PR

    Time frame: Up to approximately 24 months

  3. Disease Control Rate, DCR

    The percentage of subjects who experience CR, PR or stable disease (SD)

    Time frame: Up to approximately 24 months

  4. Progression-Free Survival, PFS

    Time from the date of first infusion to the earliest date of disease progression or death

    Time frame: Up to approximately 24 months

  5. Overall Survival, OS

    Time from the date of first infusion to the date of death

    Time frame: Up to approximately 24 months

  6. Pharmacokinetics parameter, Tmax

    Peak time

    Time frame: Up to approximately 24 months

  7. Pharmacokinetics parameter, Cmax

    Maximum concentration

    Time frame: Up to approximately 24 months

  8. Pharmacokinetics parameter, AUC

    Area under the concentration-time curve

    Time frame: Up to approximately 24 months

  9. Pharmacokinetics parameter, t1/2

    Half-life

    Time frame: Up to approximately 24 months

  10. Pharmacokinetics parameter, V

    Apparent volume of distribution

    Time frame: Up to approximately 24 months

  11. Pharmacokinetics parameter, CL

    Clearance

    Time frame: Up to approximately 24 months

  12. Immunogenicity parameter

    Anti-Drug Antibody (ADA) of 9MW2821

    Time frame: Up to approximately 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
Apr 27, 2025
StartEst.
Apr 2025
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2027
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06947226
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
Apr 2025 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 27, 2025

Study contacts

Feng Wang
Contact
fengw010@163.com
13938244776
Feng Wang
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulumtatug fuvedotin

Start the discussion